nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ABCB1—Mitoxantrone—lymphatic system cancer	0.113	0.206	CbGbCtD
Methylprednisolone—CYP3A4—Cytarabine—lymphatic system cancer	0.0986	0.18	CbGbCtD
Methylprednisolone—CYP3A4—Teniposide—lymphatic system cancer	0.0971	0.177	CbGbCtD
Methylprednisolone—ABCB1—Vincristine—lymphatic system cancer	0.078	0.142	CbGbCtD
Methylprednisolone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0679	0.124	CbGbCtD
Methylprednisolone—ABCB1—Methotrexate—lymphatic system cancer	0.0472	0.086	CbGbCtD
Methylprednisolone—CYP3A4—Vincristine—lymphatic system cancer	0.0467	0.0851	CbGbCtD
Methylprednisolone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0012	0.00265	CcSEcCtD
Methylprednisolone—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00119	0.00264	CcSEcCtD
Methylprednisolone—Infection—Teniposide—lymphatic system cancer	0.00119	0.00264	CcSEcCtD
Methylprednisolone—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00119	0.00263	CcSEcCtD
Methylprednisolone—Tachycardia—Teniposide—lymphatic system cancer	0.00117	0.00259	CcSEcCtD
Methylprednisolone—Malaise—Fludarabine—lymphatic system cancer	0.00116	0.00258	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00116	0.00257	CcSEcCtD
Methylprednisolone—Muscular weakness—Vincristine—lymphatic system cancer	0.00115	0.00256	CcSEcCtD
Methylprednisolone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00115	0.00255	CcSEcCtD
Methylprednisolone—Fungal infection—Methotrexate—lymphatic system cancer	0.00113	0.00251	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00112	0.00249	CcSEcCtD
Methylprednisolone—Hypotension—Teniposide—lymphatic system cancer	0.00112	0.00248	CcSEcCtD
Methylprednisolone—Convulsion—Fludarabine—lymphatic system cancer	0.00112	0.00248	CcSEcCtD
Methylprednisolone—Necrosis—Methotrexate—lymphatic system cancer	0.00111	0.00247	CcSEcCtD
Methylprednisolone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00111	0.00246	CcSEcCtD
Methylprednisolone—Abscess—Methotrexate—lymphatic system cancer	0.0011	0.00245	CcSEcCtD
Methylprednisolone—Myalgia—Fludarabine—lymphatic system cancer	0.0011	0.00243	CcSEcCtD
Methylprednisolone—Arthralgia—Fludarabine—lymphatic system cancer	0.0011	0.00243	CcSEcCtD
Methylprednisolone—Haemoglobin—Bleomycin—lymphatic system cancer	0.00109	0.00242	CcSEcCtD
Methylprednisolone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00109	0.00241	CcSEcCtD
Methylprednisolone—Discomfort—Fludarabine—lymphatic system cancer	0.00108	0.0024	CcSEcCtD
Methylprednisolone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00107	0.00238	CcSEcCtD
Methylprednisolone—Petechiae—Methotrexate—lymphatic system cancer	0.00106	0.00236	CcSEcCtD
Methylprednisolone—Confusional state—Fludarabine—lymphatic system cancer	0.00106	0.00235	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00105	0.00233	CcSEcCtD
Methylprednisolone—Infection—Fludarabine—lymphatic system cancer	0.00104	0.00232	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00103	0.00229	CcSEcCtD
Methylprednisolone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00103	0.00229	CcSEcCtD
Methylprednisolone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00103	0.00229	CcSEcCtD
Methylprednisolone—Rash—Mechlorethamine—lymphatic system cancer	0.00102	0.00227	CcSEcCtD
Methylprednisolone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00102	0.00227	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00102	0.00225	CcSEcCtD
Methylprednisolone—Weight increased—Mitoxantrone—lymphatic system cancer	0.001	0.00222	CcSEcCtD
Methylprednisolone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000993	0.0022	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000988	0.00219	CcSEcCtD
Methylprednisolone—Myocardial infarction—Vincristine—lymphatic system cancer	0.000988	0.00219	CcSEcCtD
Methylprednisolone—Feeling abnormal—Teniposide—lymphatic system cancer	0.000986	0.00219	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000979	0.00217	CcSEcCtD
Methylprednisolone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000967	0.00215	CcSEcCtD
Methylprednisolone—Sweating—Vincristine—lymphatic system cancer	0.000966	0.00214	CcSEcCtD
Methylprednisolone—Nausea—Mechlorethamine—lymphatic system cancer	0.000964	0.00214	CcSEcCtD
Methylprednisolone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000962	0.00213	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000958	0.00213	CcSEcCtD
Methylprednisolone—Haemoglobin—Carmustine—lymphatic system cancer	0.000952	0.00211	CcSEcCtD
Methylprednisolone—Urticaria—Teniposide—lymphatic system cancer	0.000951	0.00211	CcSEcCtD
Methylprednisolone—Haemorrhage—Carmustine—lymphatic system cancer	0.000947	0.0021	CcSEcCtD
Methylprednisolone—Abdominal pain—Teniposide—lymphatic system cancer	0.000946	0.0021	CcSEcCtD
Methylprednisolone—Erythema—Bleomycin—lymphatic system cancer	0.000945	0.0021	CcSEcCtD
Methylprednisolone—Paraesthesia—Fludarabine—lymphatic system cancer	0.000944	0.00209	CcSEcCtD
Methylprednisolone—Hallucination—Carmustine—lymphatic system cancer	0.000943	0.00209	CcSEcCtD
Methylprednisolone—Sweating—Mitoxantrone—lymphatic system cancer	0.000941	0.00209	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000931	0.00206	CcSEcCtD
Methylprednisolone—Dyspepsia—Fludarabine—lymphatic system cancer	0.000926	0.00205	CcSEcCtD
Methylprednisolone—Visual impairment—Carmustine—lymphatic system cancer	0.000913	0.00202	CcSEcCtD
Methylprednisolone—Fatigue—Fludarabine—lymphatic system cancer	0.000907	0.00201	CcSEcCtD
Methylprednisolone—Inflammation—Methotrexate—lymphatic system cancer	0.000901	0.002	CcSEcCtD
Methylprednisolone—Hallucination—Vincristine—lymphatic system cancer	0.0009	0.002	CcSEcCtD
Methylprednisolone—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000897	0.00199	CcSEcCtD
Methylprednisolone—Vasculitis—Methotrexate—lymphatic system cancer	0.000895	0.00199	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000889	0.00197	CcSEcCtD
Methylprednisolone—Eye disorder—Carmustine—lymphatic system cancer	0.000885	0.00196	CcSEcCtD
Methylprednisolone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000885	0.00196	CcSEcCtD
Methylprednisolone—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000883	0.00196	CcSEcCtD
Methylprednisolone—Hypersensitivity—Teniposide—lymphatic system cancer	0.000882	0.00196	CcSEcCtD
Methylprednisolone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000881	0.00195	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000877	0.00194	CcSEcCtD
Methylprednisolone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000867	0.00192	CcSEcCtD
Methylprednisolone—Asthenia—Teniposide—lymphatic system cancer	0.000859	0.0019	CcSEcCtD
Methylprednisolone—Malaise—Bleomycin—lymphatic system cancer	0.000852	0.00189	CcSEcCtD
Methylprednisolone—Pruritus—Teniposide—lymphatic system cancer	0.000847	0.00188	CcSEcCtD
Methylprednisolone—Arrhythmia—Carmustine—lymphatic system cancer	0.000846	0.00188	CcSEcCtD
Methylprednisolone—Cardiac disorder—Vincristine—lymphatic system cancer	0.000839	0.00186	CcSEcCtD
Methylprednisolone—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000834	0.00185	CcSEcCtD
Methylprednisolone—Mental disorder—Carmustine—lymphatic system cancer	0.00083	0.00184	CcSEcCtD
Methylprednisolone—Erythema—Carmustine—lymphatic system cancer	0.000825	0.00183	CcSEcCtD
Methylprednisolone—Malnutrition—Carmustine—lymphatic system cancer	0.000825	0.00183	CcSEcCtD
Methylprednisolone—Angiopathy—Vincristine—lymphatic system cancer	0.000821	0.00182	CcSEcCtD
Methylprednisolone—Diarrhoea—Teniposide—lymphatic system cancer	0.000819	0.00182	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000815	0.00181	CcSEcCtD
Methylprednisolone—Myalgia—Bleomycin—lymphatic system cancer	0.000804	0.00178	CcSEcCtD
Methylprednisolone—Discomfort—Bleomycin—lymphatic system cancer	0.000795	0.00176	CcSEcCtD
Methylprednisolone—Mental disorder—Vincristine—lymphatic system cancer	0.000792	0.00176	CcSEcCtD
Methylprednisolone—Ecchymosis—Methotrexate—lymphatic system cancer	0.00079	0.00175	CcSEcCtD
Methylprednisolone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000787	0.00175	CcSEcCtD
Methylprednisolone—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000778	0.00173	CcSEcCtD
Methylprednisolone—Confusional state—Bleomycin—lymphatic system cancer	0.000778	0.00172	CcSEcCtD
Methylprednisolone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000775	0.00172	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000771	0.00171	CcSEcCtD
Methylprednisolone—Erythema—Mitoxantrone—lymphatic system cancer	0.000767	0.0017	CcSEcCtD
Methylprednisolone—Infection—Bleomycin—lymphatic system cancer	0.000766	0.0017	CcSEcCtD
Methylprednisolone—Vomiting—Teniposide—lymphatic system cancer	0.000761	0.00169	CcSEcCtD
Methylprednisolone—Asthenia—Fludarabine—lymphatic system cancer	0.000755	0.00167	CcSEcCtD
Methylprednisolone—Rash—Teniposide—lymphatic system cancer	0.000755	0.00167	CcSEcCtD
Methylprednisolone—Dermatitis—Teniposide—lymphatic system cancer	0.000754	0.00167	CcSEcCtD
Methylprednisolone—Headache—Teniposide—lymphatic system cancer	0.00075	0.00166	CcSEcCtD
Methylprednisolone—Pruritus—Fludarabine—lymphatic system cancer	0.000744	0.00165	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000733	0.00163	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000729	0.00162	CcSEcCtD
Methylprednisolone—Hypotension—Bleomycin—lymphatic system cancer	0.000721	0.0016	CcSEcCtD
Methylprednisolone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00072	0.0016	CcSEcCtD
Methylprednisolone—Convulsion—Carmustine—lymphatic system cancer	0.000715	0.00158	CcSEcCtD
Methylprednisolone—Hypertension—Carmustine—lymphatic system cancer	0.000712	0.00158	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000711	0.00158	CcSEcCtD
Methylprednisolone—Nausea—Teniposide—lymphatic system cancer	0.000711	0.00158	CcSEcCtD
Methylprednisolone—Vertigo—Vincristine—lymphatic system cancer	0.000707	0.00157	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000703	0.00156	CcSEcCtD
Methylprednisolone—Myalgia—Carmustine—lymphatic system cancer	0.000702	0.00156	CcSEcCtD
Methylprednisolone—Anxiety—Carmustine—lymphatic system cancer	0.0007	0.00155	CcSEcCtD
Methylprednisolone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000692	0.00154	CcSEcCtD
Methylprednisolone—Malaise—Mitoxantrone—lymphatic system cancer	0.000691	0.00153	CcSEcCtD
Methylprednisolone—Convulsion—Vincristine—lymphatic system cancer	0.000682	0.00151	CcSEcCtD
Methylprednisolone—Hypertension—Vincristine—lymphatic system cancer	0.00068	0.00151	CcSEcCtD
Methylprednisolone—Confusional state—Carmustine—lymphatic system cancer	0.000679	0.00151	CcSEcCtD
Methylprednisolone—Myalgia—Vincristine—lymphatic system cancer	0.00067	0.00149	CcSEcCtD
Methylprednisolone—Infection—Carmustine—lymphatic system cancer	0.000669	0.00148	CcSEcCtD
Methylprednisolone—Vomiting—Fludarabine—lymphatic system cancer	0.000669	0.00148	CcSEcCtD
Methylprednisolone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000664	0.00147	CcSEcCtD
Methylprednisolone—Rash—Fludarabine—lymphatic system cancer	0.000663	0.00147	CcSEcCtD
Methylprednisolone—Dermatitis—Fludarabine—lymphatic system cancer	0.000663	0.00147	CcSEcCtD
Methylprednisolone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000662	0.00147	CcSEcCtD
Methylprednisolone—Headache—Fludarabine—lymphatic system cancer	0.000659	0.00146	CcSEcCtD
Methylprednisolone—Tachycardia—Carmustine—lymphatic system cancer	0.000657	0.00146	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000655	0.00145	CcSEcCtD
Methylprednisolone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000653	0.00145	CcSEcCtD
Methylprednisolone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000653	0.00145	CcSEcCtD
Methylprednisolone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000651	0.00144	CcSEcCtD
Methylprednisolone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000645	0.00143	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000643	0.00143	CcSEcCtD
Methylprednisolone—Infection—Vincristine—lymphatic system cancer	0.000638	0.00142	CcSEcCtD
Methylprednisolone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000635	0.00141	CcSEcCtD
Methylprednisolone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000634	0.00141	CcSEcCtD
Methylprednisolone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000631	0.0014	CcSEcCtD
Methylprednisolone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00063	0.0014	CcSEcCtD
Methylprednisolone—Hypotension—Carmustine—lymphatic system cancer	0.000629	0.00139	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000626	0.00139	CcSEcCtD
Methylprednisolone—Nausea—Fludarabine—lymphatic system cancer	0.000625	0.00139	CcSEcCtD
Methylprednisolone—Infection—Mitoxantrone—lymphatic system cancer	0.000622	0.00138	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000621	0.00138	CcSEcCtD
Methylprednisolone—Shock—Mitoxantrone—lymphatic system cancer	0.000616	0.00137	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000613	0.00136	CcSEcCtD
Methylprednisolone—Urticaria—Bleomycin—lymphatic system cancer	0.000613	0.00136	CcSEcCtD
Methylprednisolone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000611	0.00135	CcSEcCtD
Methylprednisolone—Insomnia—Carmustine—lymphatic system cancer	0.000609	0.00135	CcSEcCtD
Methylprednisolone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000608	0.00135	CcSEcCtD
Methylprednisolone—Irritability—Methotrexate—lymphatic system cancer	0.000605	0.00134	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000605	0.00134	CcSEcCtD
Methylprednisolone—Paraesthesia—Carmustine—lymphatic system cancer	0.000604	0.00134	CcSEcCtD
Methylprednisolone—Mood swings—Methotrexate—lymphatic system cancer	0.000601	0.00133	CcSEcCtD
Methylprednisolone—Hypotension—Vincristine—lymphatic system cancer	0.0006	0.00133	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000585	0.0013	CcSEcCtD
Methylprednisolone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000585	0.0013	CcSEcCtD
Methylprednisolone—Insomnia—Vincristine—lymphatic system cancer	0.000581	0.00129	CcSEcCtD
Methylprednisolone—Paraesthesia—Vincristine—lymphatic system cancer	0.000577	0.00128	CcSEcCtD
Methylprednisolone—Breast disorder—Methotrexate—lymphatic system cancer	0.000573	0.00127	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00057	0.00126	CcSEcCtD
Methylprednisolone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000568	0.00126	CcSEcCtD
Methylprednisolone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000562	0.00125	CcSEcCtD
Methylprednisolone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000555	0.00123	CcSEcCtD
Methylprednisolone—Fatigue—Vincristine—lymphatic system cancer	0.000554	0.00123	CcSEcCtD
Methylprednisolone—Asthenia—Bleomycin—lymphatic system cancer	0.000553	0.00123	CcSEcCtD
Methylprednisolone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000551	0.00122	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00055	0.00122	CcSEcCtD
Methylprednisolone—Pruritus—Bleomycin—lymphatic system cancer	0.000546	0.00121	CcSEcCtD
Methylprednisolone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00054	0.0012	CcSEcCtD
Methylprednisolone—Pancreatitis—Methotrexate—lymphatic system cancer	0.000538	0.00119	CcSEcCtD
Methylprednisolone—Abdominal pain—Carmustine—lymphatic system cancer	0.000532	0.00118	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000525	0.00117	CcSEcCtD
Methylprednisolone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000516	0.00114	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000512	0.00113	CcSEcCtD
Methylprednisolone—Abdominal pain—Vincristine—lymphatic system cancer	0.000508	0.00113	CcSEcCtD
Methylprednisolone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000497	0.0011	CcSEcCtD
Methylprednisolone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000496	0.0011	CcSEcCtD
Methylprednisolone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000495	0.0011	CcSEcCtD
Methylprednisolone—Vomiting—Bleomycin—lymphatic system cancer	0.00049	0.00109	CcSEcCtD
Methylprednisolone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000489	0.00108	CcSEcCtD
Methylprednisolone—Infestation—Methotrexate—lymphatic system cancer	0.000489	0.00108	CcSEcCtD
Methylprednisolone—Rash—Bleomycin—lymphatic system cancer	0.000486	0.00108	CcSEcCtD
Methylprednisolone—Dermatitis—Bleomycin—lymphatic system cancer	0.000486	0.00108	CcSEcCtD
Methylprednisolone—Asthenia—Carmustine—lymphatic system cancer	0.000483	0.00107	CcSEcCtD
Methylprednisolone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000473	0.00105	CcSEcCtD
Methylprednisolone—Sweating—Methotrexate—lymphatic system cancer	0.000469	0.00104	CcSEcCtD
Methylprednisolone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000461	0.00102	CcSEcCtD
Methylprednisolone—Asthenia—Vincristine—lymphatic system cancer	0.000461	0.00102	CcSEcCtD
Methylprednisolone—Diarrhoea—Carmustine—lymphatic system cancer	0.000461	0.00102	CcSEcCtD
Methylprednisolone—Nausea—Bleomycin—lymphatic system cancer	0.000458	0.00102	CcSEcCtD
Methylprednisolone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000449	0.000996	CcSEcCtD
Methylprednisolone—Dizziness—Carmustine—lymphatic system cancer	0.000445	0.000987	CcSEcCtD
Methylprednisolone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000441	0.000978	CcSEcCtD
Methylprednisolone—Diarrhoea—Vincristine—lymphatic system cancer	0.00044	0.000975	CcSEcCtD
Methylprednisolone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000439	0.000973	CcSEcCtD
Methylprednisolone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000428	0.00095	CcSEcCtD
Methylprednisolone—Vomiting—Carmustine—lymphatic system cancer	0.000428	0.000949	CcSEcCtD
Methylprednisolone—Dizziness—Vincristine—lymphatic system cancer	0.000425	0.000942	CcSEcCtD
Methylprednisolone—Rash—Carmustine—lymphatic system cancer	0.000424	0.000941	CcSEcCtD
Methylprednisolone—Dermatitis—Carmustine—lymphatic system cancer	0.000424	0.00094	CcSEcCtD
Methylprednisolone—Visual impairment—Methotrexate—lymphatic system cancer	0.000423	0.000938	CcSEcCtD
Methylprednisolone—Headache—Carmustine—lymphatic system cancer	0.000422	0.000935	CcSEcCtD
Methylprednisolone—Eye disorder—Methotrexate—lymphatic system cancer	0.00041	0.00091	CcSEcCtD
Methylprednisolone—Vomiting—Vincristine—lymphatic system cancer	0.000409	0.000906	CcSEcCtD
Methylprednisolone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000407	0.000903	CcSEcCtD
Methylprednisolone—Rash—Vincristine—lymphatic system cancer	0.000405	0.000899	CcSEcCtD
Methylprednisolone—Dermatitis—Vincristine—lymphatic system cancer	0.000405	0.000898	CcSEcCtD
Methylprednisolone—Headache—Vincristine—lymphatic system cancer	0.000403	0.000893	CcSEcCtD
Methylprednisolone—Nausea—Carmustine—lymphatic system cancer	0.0004	0.000887	CcSEcCtD
Methylprednisolone—Angiopathy—Methotrexate—lymphatic system cancer	0.000398	0.000883	CcSEcCtD
Methylprednisolone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000398	0.000882	CcSEcCtD
Methylprednisolone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000396	0.000879	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000396	0.000877	CcSEcCtD
Methylprednisolone—Rash—Mitoxantrone—lymphatic system cancer	0.000395	0.000875	CcSEcCtD
Methylprednisolone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000394	0.000874	CcSEcCtD
Methylprednisolone—Headache—Mitoxantrone—lymphatic system cancer	0.000392	0.000869	CcSEcCtD
Methylprednisolone—Mental disorder—Methotrexate—lymphatic system cancer	0.000384	0.000853	CcSEcCtD
Methylprednisolone—Malnutrition—Methotrexate—lymphatic system cancer	0.000382	0.000847	CcSEcCtD
Methylprednisolone—Erythema—Methotrexate—lymphatic system cancer	0.000382	0.000847	CcSEcCtD
Methylprednisolone—Nausea—Vincristine—lymphatic system cancer	0.000382	0.000846	CcSEcCtD
Methylprednisolone—Nausea—Mitoxantrone—lymphatic system cancer	0.000372	0.000824	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000354	0.000786	CcSEcCtD
Methylprednisolone—Malaise—Methotrexate—lymphatic system cancer	0.000345	0.000764	CcSEcCtD
Methylprednisolone—Vertigo—Methotrexate—lymphatic system cancer	0.000343	0.000761	CcSEcCtD
Methylprednisolone—Convulsion—Methotrexate—lymphatic system cancer	0.000331	0.000734	CcSEcCtD
Methylprednisolone—Myalgia—Methotrexate—lymphatic system cancer	0.000325	0.000721	CcSEcCtD
Methylprednisolone—Arthralgia—Methotrexate—lymphatic system cancer	0.000325	0.000721	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000323	0.000716	CcSEcCtD
Methylprednisolone—Discomfort—Methotrexate—lymphatic system cancer	0.000321	0.000713	CcSEcCtD
Methylprednisolone—Confusional state—Methotrexate—lymphatic system cancer	0.000314	0.000697	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000312	0.000691	CcSEcCtD
Methylprednisolone—Infection—Methotrexate—lymphatic system cancer	0.00031	0.000687	CcSEcCtD
Methylprednisolone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000306	0.000678	CcSEcCtD
Methylprednisolone—Skin disorder—Methotrexate—lymphatic system cancer	0.000303	0.000672	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000301	0.000668	CcSEcCtD
Methylprednisolone—Hypotension—Methotrexate—lymphatic system cancer	0.000291	0.000646	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000284	0.00063	CcSEcCtD
Methylprednisolone—Insomnia—Methotrexate—lymphatic system cancer	0.000282	0.000625	CcSEcCtD
Methylprednisolone—Paraesthesia—Methotrexate—lymphatic system cancer	0.00028	0.000621	CcSEcCtD
Methylprednisolone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000274	0.000609	CcSEcCtD
Methylprednisolone—Fatigue—Methotrexate—lymphatic system cancer	0.000269	0.000596	CcSEcCtD
Methylprednisolone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000257	0.00057	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000255	0.000565	CcSEcCtD
Methylprednisolone—Urticaria—Methotrexate—lymphatic system cancer	0.000248	0.000549	CcSEcCtD
Methylprednisolone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000246	0.000547	CcSEcCtD
Methylprednisolone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00023	0.000509	CcSEcCtD
Methylprednisolone—Asthenia—Methotrexate—lymphatic system cancer	0.000224	0.000496	CcSEcCtD
Methylprednisolone—Pruritus—Methotrexate—lymphatic system cancer	0.000221	0.000489	CcSEcCtD
Methylprednisolone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000213	0.000473	CcSEcCtD
Methylprednisolone—Dizziness—Methotrexate—lymphatic system cancer	0.000206	0.000457	CcSEcCtD
Methylprednisolone—Vomiting—Methotrexate—lymphatic system cancer	0.000198	0.00044	CcSEcCtD
Methylprednisolone—Rash—Methotrexate—lymphatic system cancer	0.000197	0.000436	CcSEcCtD
Methylprednisolone—Dermatitis—Methotrexate—lymphatic system cancer	0.000196	0.000436	CcSEcCtD
Methylprednisolone—Headache—Methotrexate—lymphatic system cancer	0.000195	0.000433	CcSEcCtD
Methylprednisolone—Nausea—Methotrexate—lymphatic system cancer	0.000185	0.000411	CcSEcCtD
